
Elevai Labs, Common Stock (ELAB) Stock
Elevai Labs, Common Stock Chart
Company Profile
Price: $1.91
Market Cap: $5.87M
Exchange: NASDAQ
CEO: Mr. Graydon Bensler C.F.A.
Sector: Healthcare
Industry: Biotechnology
Employees: -0.00B
Headquarters: None, None
Website: Elevai Labs, Common Stock
Business Summary
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Elevai Labs, Common Stock News
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fir

Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)
New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the completion of the previously announced warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), a diversified holding company, for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024.

PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors
NEWPORT BEACH, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024.

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture
NEWPORT BEACH, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced the closing of the previously announced divestiture of its 100% wholly owned subsidiary Elevai Skincare Inc. (“Elevai”) pursuant to a definitive purchase agreement with Carmell Corporation (“Carmell”) (the “Divestiture”) and reaffirms its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare.

PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries
PMGC Research Inc., formerly Elevai Research Inc., is a development company focused on public-private collaborations leveraging research grants. Northstrive Biosciences Inc., formerly Elevai Biosciences, Inc., is a biopharmaceutical company targeting obesity with next-generation treatments.

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare.

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products
Carmell and PMGC Holdings Inc Announce Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair

Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it completed a strategic reorganization.

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic reorganization effective on December 20, 2024. This reorganization will include changing the Company's name from Elevai Labs Inc. to PMGC Holdings Inc. and redomiciling from Delaware to Nevada. After this reorganization, the Company will continue to trade on The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “ELAB.” The redomestication and name change will be effective on Nasdaq at the opening of business on December 23, 2024.

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (Elevai" or the "Company") announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock Split”) of its common stock, which will be effective at midnight on November 27, 2024.

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has withdrawn the previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), as a result of notice from the Depositary Trust Company (“DTC”) that due to logistical issues, DTC would not be able to accept the tenders of Common Stock.

CORRECTION - Elevai Labs Inc.
NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc. (NASDAQ: ELAB), please note that in the headline and first paragraph, the financial results are from the company's third fiscal quarter of 2024, not the second fiscal quarter as previously stated; as such, the header over the first bullet list should note the financial results as being from the three and nine months ended September 30, 2024, rather than the three and six months ended June 30, 2024 as previous stated.

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation. Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation.

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025 Muscle wasting is a common side effect of popular GLP-1 weight-loss medications, with no current approved treatments.

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an offer to exchange up to 15,000,000 shares of its currently issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)
New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered follow-on offering (the “Offering”) of approximately $8.0 million for its client Elevai Labs Inc. (NASDAQ: ELAB) (the “Company”), a pioneering force in medical aesthetics.

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months.

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance.

Elevai Labs, Common Stock Earnings
This section highlights Elevai Labs, Common Stock's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|
Financial Statements
Access annual & quarterly financial statements for Elevai Labs, Common Stock, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|
Revenue | $1.71M | $766.28K | $-0.00B | $- |
Cost of Revenue | $578.01K | $324.00K | $2.85K | $- |
Gross Profit | $1.13M | $442.27K | $-2.02K | $- |
Gross Profit Ratio | 66.25% | 57.72% | -244.01% | 0.00% |
Research and Development Expenses | $426.24K | $228.75K | $123.63K | $118.86K |
General and Administrative Expenses | $3.37M | $1.54M | $602.73K | $95.94K |
Selling and Marketing Expenses | $660.29K | $192.86K | $31.61K | $6.08K |
Selling General and Administrative Expenses | $4.03M | $1.80M | $633.96K | $102.99K |
Other Expenses | $-3.32M | $-198.44K | $-25.45K | $- |
Operating Expenses | $1.13M | $2.23M | $783.04K | $222.91K |
Cost and Expenses | $5.47M | $2.55M | $785.89K | $222.91K |
Interest Income | $5.56K | $7.70K | $- | $- |
Interest Expense | $19.52K | $2.63K | $- | $- |
Depreciation and Amortization | $11.65K | $6.51K | $2.76K | $221.84K |
EBITDA | $-4.27M | $-1.78M | $-782.30K | $-1.07K |
EBITDA Ratio | -249.35% | -232.52% | -94594.92% | 0.00% |
Operating Income | $-3.67M | $-1.79M | $-785.06K | $-221.84K |
Operating Income Ratio | -214.24% | -233.37% | -94928.66% | 0.00% |
Total Other Income Expenses Net | $-632.45K | $-11.98K | $-0.00B | $-1.07K |
Income Before Tax | $-4.30M | $-1.80M | $-784.74K | $-222.91K |
Income Before Tax Ratio | -251.17% | -234.94% | -94889.84% | 0.00% |
Income Tax Expense | $- | $--0.00B | $-0.00B | $-1.07K |
Net Income | $-4.30M | $-1.80M | $-784.74K | $-222.91K |
Net Income Ratio | -251.17% | -234.94% | -94889.84% | 0.00% |
EPS | $-0.40 | $-0.19 | $-0.05 | $-0.05 |
EPS Diluted | $-0.40 | $-0.19 | $-0.05 | $-0.05 |
Weighted Average Shares Outstanding | 10.75M | 9.53M | 17.33M | 4.41M |
Weighted Average Shares Outstanding Diluted | 10.75M | 9.53M | 17.33M | 4.41M |
SEC Filing | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 |
---|---|---|---|---|---|---|---|---|---|
Revenue | $527.48K | $605.53K | $614.56K | $698.59K | $554.65K | $316.53K | $142.82K | $138.90K | $432.12K |
Cost of Revenue | $133.58K | $166.28K | $189.24K | $239.36K | $190.95K | $108.18K | $44.43K | $47.20K | $196.06K |
Gross Profit | $393.90K | $439.25K | $425.32K | $459.23K | $363.71K | $208.35K | $98.39K | $91.70K | $236.06K |
Gross Profit Ratio | 74.68% | 72.54% | 69.21% | 65.74% | 65.57% | 65.82% | 68.89% | 66.02% | 54.63% |
Research and Development Expenses | $95.26K | $52.38K | $103.19K | $122.47K | $86.37K | $133.65K | $83.74K | $60.86K | $89.33K |
General and Administrative Expenses | $1.04M | $1.01M | $1.45M | $971.89K | $891.36K | $848.61K | $655.82K | $549.97K | $471.45K |
Selling and Marketing Expenses | $94.51K | $721.49K | $393.04K | $343.86K | $99.71K | $114.05K | $102.68K | $58.10K | $73.27K |
Selling General and Administrative Expenses | $1.13M | $1.73M | $1.95M | $1.32M | $1.00M | $962.66K | $758.50K | $653.66K | $563.15K |
Other Expenses | $-835.03K | $66.21K | $-59.11K | $-89.15K | $-65.83K | $- | $- | $-49.95K | $-55.89K |
Operating Expenses | $393.90K | $1.85M | $2.11M | $1.53M | $1.15M | $1.26M | $944.52K | $764.47K | $708.36K |
Cost and Expenses | $527.48K | $2.01M | $2.30M | $1.77M | $1.34M | $1.37M | $988.95K | $811.66K | $904.42K |
Interest Income | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $5.11K | $4.46K | $3.16K |
Interest Expense | $648.33K | $30.81K | $23.54K | $6.77K | $5.71K | $4.41K | $2.64K | $-0.00B | $-0.00B |
Depreciation and Amortization | $-36.24K | $24.77K | $21.19K | $2.91K | $2.44K | $2.91K | $2.91K | $2.61K | $1.63K |
EBITDA | $-850.24K | $-1.36M | $-1.35M | $-1.07M | $-776.65K | $-1.05M | $-838.11K | $-670.16K | $-470.67K |
EBITDA Ratio | -161.19% | -224.09% | -270.39% | -153.37% | -141.75% | -330.99% | -586.83% | -482.48% | -108.92% |
Operating Income | $- | $-1.41M | $-1.68M | $-1.07M | $-788.66K | $-1.05M | $-841.02K | $-672.77K | $-472.30K |
Operating Income Ratio | 0.00% | -232.59% | -273.84% | -153.79% | -142.19% | -331.91% | -588.87% | -484.36% | -109.30% |
Total Other Income Expenses Net | $-1.50M | $-4.12K | $285.67K | $-83.58K | $5.62K | $-228.90K | $-234.57K | $-21.68K | $-26.78K |
Income Before Tax | $-1.50M | $-1.41M | $-1.40M | $-1.16M | $-783.05K | $-1.28M | $-1.08M | $-652.66K | $-499.08K |
Income Before Tax Ratio | -284.61% | -233.27% | -227.36% | -165.75% | -141.18% | -404.34% | -756.68% | -469.88% | -115.50% |
Income Tax Expense | $- | $- | $-0.00B | $--0.00B | $-0.00B | $4.41K | $2.64K | $--0.00B | $-25.45K |
Net Income | $-1.50M | $-1.41M | $-1.40M | $-1.16M | $-783.05K | $-1.28M | $-1.08M | $-652.66K | $-499.08K |
Net Income Ratio | -284.61% | -233.27% | -227.36% | -165.75% | -141.18% | -404.34% | -756.68% | -469.88% | -115.50% |
EPS | $-0.07 | $-0.08 | $-0.08 | $-0.07 | $-0.05 | $-0.07 | $-0.11 | $-0.07 | $-0.03 |
EPS Diluted | $-0.07 | $-0.08 | $-0.08 | $-0.07 | $-0.05 | $-0.07 | $-0.06 | $-0.07 | $-0.03 |
Weighted Average Shares Outstanding | 22.16M | 18.30M | 17.33M | 17.33M | 17.33M | 17.33M | 9.71M | 9.57M | 17.33M |
Weighted Average Shares Outstanding Diluted | 22.16M | 18.30M | 17.33M | 17.33M | 17.33M | 17.33M | 17.33M | 9.57M | 17.33M |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|
Cash and Cash Equivalents | $3.33M | $1.15M | $411.86K | $13.35K |
Short Term Investments | $- | $- | $- | $- |
Cash and Short Term Investments | $3.33M | $1.15M | $411.86K | $13.35K |
Net Receivables | $36.16K | $12.85K | $1.71K | $- |
Inventory | $495.67K | $243.75K | $191.78K | $- |
Other Current Assets | $1.06M | $153.42K | $62.14K | $3.67K |
Total Current Assets | $4.92M | $1.50M | $636.52K | $17.02K |
Property Plant Equipment Net | $259.70K | $330.09K | $29.73K | $- |
Goodwill | $- | $- | $- | $- |
Intangible Assets | $- | $- | $- | $- |
Goodwill and Intangible Assets | $- | $- | $- | $- |
Long Term Investments | $- | $10.77K | $- | $- |
Tax Assets | $- | $- | $- | $- |
Other Non-Current Assets | $10.77K | $50.00K | $- | $- |
Total Non-Current Assets | $270.47K | $390.86K | $29.73K | $- |
Other Assets | $- | $-0.00B | $- | $- |
Total Assets | $5.19M | $1.89M | $666.25K | $17.02K |
Account Payables | $596.15K | $210.84K | $98.17K | $-0.00B |
Short Term Debt | $145.00K | $110.62K | $- | $24.00K |
Tax Payables | $- | $- | $- | $- |
Deferred Revenue | $36.69K | $10.17K | $- | $- |
Other Current Liabilities | $519.51K | $256.64K | $117.45K | $16.46K |
Total Current Liabilities | $1.30M | $588.27K | $215.62K | $40.61K |
Long Term Debt | $65.49K | $172.60K | $- | $- |
Deferred Revenue Non-Current | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- |
Other Non-Current Liabilities | $- | $- | $- | $- |
Total Non-Current Liabilities | $65.49K | $172.60K | $- | $- |
Other Liabilities | $- | $- | $- | $- |
Total Liabilities | $1.36M | $760.87K | $215.62K | $40.61K |
Preferred Stock | $- | $-0.00B | $-0.00B | $-0.00B |
Common Stock | $1.73K | $-0.00B | $-0.00B | $-0.00B |
Retained Earnings | $-7.02M | $-2.72M | $-922.11K | $-137.37K |
Accumulated Other Comprehensive Income Loss | $-0.00B | $-0.00B | $-0.00B | $-1.22K |
Other Total Stockholders Equity | $10.85M | $3.85M | $1.37M | $114.13K |
Total Stockholders Equity | $3.83M | $1.13M | $450.63K | $-23.59K |
Total Equity | $3.83M | $1.13M | $450.63K | $-23.59K |
Total Liabilities and Stockholders Equity | $5.19M | $1.89M | $666.25K | $17.02K |
Minority Interest | $- | $- | $- | $- |
Total Liabilities and Total Equity | $5.19M | $1.89M | $666.25K | $17.02K |
Total Investments | $10.77K | $10.77K | $- | $- |
Total Debt | $210.49K | $283.22K | $- | $24.00K |
Net Debt | $-3.12M | $-871.68K | $-411.86K | $10.65K |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | December 31, 2022 | September 30, 2022 |
---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $6.43M | $100.03K | $943.80K | $3.33M | $476.86K | $601.26K | $1.15M | $1.15M |
Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $6.43M | $100.03K | $943.80K | $3.33M | $476.86K | $601.26K | $1.15M | $1.15M |
Net Receivables | $27.89K | $29.07K | $54.20K | $36.16K | $8.38K | $34.44K | $12.85K | $12.85K |
Inventory | $986.42K | $978.55K | $945.06K | $598.79K | $510.15K | $477.86K | $243.75K | $243.75K |
Other Current Assets | $787.85K | $923.44K | $1.20M | $1.06M | $292.06K | $336.94K | $153.42K | $89.82K |
Total Current Assets | $8.23M | $2.03M | $3.14M | $4.92M | $1.04M | $1.45M | $1.50M | $1.50M |
Property Plant Equipment Net | $154.00K | $193.29K | $231.56K | $259.70K | $295.61K | $282.68K | $330.09K | $330.09K |
Goodwill | $- | $- | $- | $- | $- | $- | $- | $- |
Intangible Assets | $2.82M | $2.85M | $843.50K | $- | $- | $- | $- | $- |
Goodwill and Intangible Assets | $2.82M | $2.85M | $843.50K | $- | $- | $- | $- | $- |
Long Term Investments | $- | $10.77K | $10.77K | $10.77K | $10.77K | $- | $10.77K | $10.77K |
Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- |
Other Non-Current Assets | $- | $- | $--0.00B | $--0.00B | $236.94K | $10.77K | $50.00K | $50.00K |
Total Non-Current Assets | $2.98M | $3.05M | $1.09M | $270.47K | $543.33K | $293.45K | $390.86K | $390.86K |
Other Assets | $- | $- | $-0.00B | $-0.00B | $-0.00B | $- | $-0.00B | $-0.00B |
Total Assets | $11.21M | $5.08M | $4.23M | $5.19M | $1.58M | $1.74M | $1.89M | $1.89M |
Account Payables | $1.08M | $1.14M | $395.25K | $596.15K | $573.05K | $537.60K | $210.84K | $222.46K |
Short Term Debt | $103.31K | $140.06K | $149.21K | $145.00K | $140.91K | $115.11K | $110.62K | $110.62K |
Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Revenue | $39.58K | $24.31K | $35.15K | $36.69K | $54.85K | $85.37K | $10.17K | $- |
Other Current Liabilities | $908.91K | $630.21K | $642.52K | $519.51K | $874.76K | $824.69K | $256.64K | $255.19K |
Total Current Liabilities | $2.13M | $1.94M | $1.22M | $1.30M | $1.64M | $1.56M | $588.27K | $588.27K |
Long Term Debt | $- | $- | $26.57K | $65.49K | $103.31K | $113.90K | $172.60K | $- |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- |
Other Non-Current Liabilities | $519.71K | $505.36K | $491.56K | $- | $- | $- | $- | $- |
Total Non-Current Liabilities | $519.71K | $505.36K | $518.13K | $65.49K | $103.31K | $113.90K | $172.60K | $172.60K |
Other Liabilities | $- | $-0.00B | $- | $- | $- | $- | $- | $- |
Total Liabilities | $2.65M | $2.44M | $1.74M | $1.36M | $1.75M | $1.68M | $760.87K | $760.87K |
Preferred Stock | $- | $- | $- | $- | $-0.00B | $-0.00B | $-0.00B | $-0.00B |
Common Stock | $4.94K | $1.89K | $1.73K | $1.73K | $1.01K | $-0.00B | $-0.00B | $-0.00B |
Retained Earnings | $-11.33M | $-9.83M | $-8.42M | $-7.02M | $-5.87M | $-5.08M | $-2.72M | $-2.72M |
Accumulated Other Comprehensive Income Loss | $-0.00B | $1.24K | $1.38K | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B |
Other Total Stockholders Equity | $19.88M | $12.47M | $10.90M | $10.85M | $5.70M | $5.15M | $3.85M | $3.85M |
Total Stockholders Equity | $8.56M | $2.64M | $2.49M | $3.83M | $-163.90K | $67.29K | $1.13M | $1.13M |
Total Equity | $8.56M | $2.64M | $2.49M | $3.83M | $-163.90K | $67.29K | $1.13M | $1.13M |
Total Liabilities and Stockholders Equity | $11.21M | $5.08M | $4.23M | $5.19M | $1.58M | $1.74M | $1.89M | $1.89M |
Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities and Total Equity | $11.21M | $5.08M | $4.23M | $5.19M | $1.58M | $1.74M | $1.89M | $1.89M |
Total Investments | $- | $10.77K | $10.77K | $10.77K | $10.77K | $- | $10.77K | $10.77K |
Total Debt | $103.31K | $140.06K | $175.78K | $210.49K | $244.22K | $229.01K | $283.22K | $283.22K |
Net Debt | $-6.32M | $40.03K | $-768.02K | $-3.12M | $-232.64K | $-372.25K | $-871.68K | $-871.68K |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|
Net Income | $-4.30M | $-1.80M | $-784.74K | $-222.91K |
Depreciation and Amortization | $11.65K | $6.51K | $2.76K | $- |
Deferred Income Tax | $- | $- | $- | $- |
Stock Based Compensation | $487.74K | $171.87K | $142.35K | $- |
Change in Working Capital | $-823.19K | $12.43K | $-21.91K | $6.79K |
Accounts Receivables | $-23.22K | $-11.55K | $-1.35K | $--0.00B |
Inventory | $-265.52K | $-69.33K | $-160.82K | $- |
Accounts Payables | $466.89K | $65.19K | $192.09K | $- |
Other Working Capital | $-1.00M | $28.12K | $-51.82K | $7.39K |
Other Non Cash Items | $68.51K | $224.16K | $118.56K | $-1.04K |
Net Cash Provided by Operating Activities | $-4.56M | $-1.59M | $-660.93K | $-217.16K |
Investments in Property Plant and Equipment | $-11.19K | $-35.53K | $-32.48K | $- |
Acquisitions Net | $- | $3.50K | $- | $- |
Purchases of Investments | $- | $- | $- | $- |
Sales Maturities of Investments | $- | $- | $- | $- |
Other Investing Activities | $- | $3.50K | $- | $- |
Net Cash Used for Investing Activities | $-11.19K | $-32.03K | $-32.48K | $- |
Debt Repayment | $- | $183.97K | $- | $- |
Common Stock Issued | $7.46M | $2.18M | $1.09M | $- |
Common Stock Repurchased | $- | $- | $- | $- |
Dividends Paid | $- | $- | $- | $- |
Other Financing Activities | $-724.70K | $2.18M | $1.09M | $238.28K |
Net Cash Used Provided by Financing Activities | $6.74M | $2.36M | $1.09M | $238.28K |
Effect of Forex Changes on Cash | $1.06K | $-1.31K | $1.35K | $-1.51K |
Net Change in Cash | $2.17M | $743.04K | $398.51K | $19.61K |
Cash at End of Period | $3.33M | $1.15M | $411.86K | $19.61K |
Cash at Beginning of Period | $1.15M | $411.86K | $13.35K | $- |
Operating Cash Flow | $-4.56M | $-1.59M | $-660.93K | $-217.16K |
Capital Expenditure | $-11.19K | $-35.53K | $-32.48K | $- |
Free Cash Flow | $-4.57M | $-1.62M | $-693.41K | $-217.16K |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 |
---|---|---|---|---|---|---|---|---|---|
Net Income | $-1.50M | $-1.41M | $-1.40M | $-1.16M | $-783.05K | $-1.28M | $-1.08M | $-652.66K | $-499.08K |
Depreciation and Amortization | $-36.24K | $24.77K | $21.19K | $2.91K | $2.91K | $2.91K | $2.91K | $2.61K | $1.70K |
Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Stock Based Compensation | $47.04K | $-44.85K | $55.34K | $141.19K | $161.48K | $109.91K | $75.16K | $77.77K | $35.59K |
Change in Working Capital | $484.67K | $656.12K | $-746.71K | $-993.86K | $113.14K | $176.50K | $-118.97K | $83.57K | $-146.43K |
Accounts Receivables | $1.31K | $25.08K | $-18.12K | $-27.73K | $25.99K | $11.77K | $-33.25K | $2.26K | $-11.57K |
Inventory | $-7.87K | $-33.48K | $-449.40K | $3.64K | $-21.45K | $-164.35K | $-83.36K | $-49.46K | $31.57K |
Accounts Payables | $173.01K | $350.81K | $-140.70K | $17.61K | $74.23K | $244.57K | $130.48K | $71.02K | $- |
Other Working Capital | $318.22K | $313.72K | $-138.50K | $-987.39K | $-30.51K | $15.63K | $59.56K | $59.74K | $-166.43K |
Other Non Cash Items | $624.12K | $-4.24K | $449.29K | $-226.99K | $--0.00B | $--0.00B | $--0.00B | $41.47K | $18.08K |
Net Cash Provided by Operating Activities | $-381.68K | $-780.69K | $-2.32M | $-2.39M | $-514.40K | $-768.76K | $-885.51K | $-506.40K | $-590.14K |
Investments in Property Plant and Equipment | $-50.00K | $- | $-59.16K | $- | $- | $- | $-11.19K | $1.40K | $-29.99K |
Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Investing Activities | $- | $-62.32K | $-50.00K | $- | $- | $- | $- | $- | $- |
Net Cash Used for Investing Activities | $-50.00K | $-62.32K | $-59.16K | $- | $- | $- | $-11.19K | $1.40K | $-29.99K |
Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $-1.98K |
Common Stock Issued | $6.99M | $- | $- | $6.00M | $390.00K | $323.59K | $750.00K | $122.10K | $1.81M |
Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $-2.07M | $- |
Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Financing Activities | $-235.56K | $- | $- | $-762.20K | $- | $- | $37.50K | $87.10K | $- |
Net Cash Used Provided by Financing Activities | $6.76M | $- | $- | $5.24M | $390.00K | $323.59K | $787.50K | $87.10K | $1.80M |
Effect of Forex Changes on Cash | $--0.00B | $--0.00B | $-0.00B | $-0.00B | $--0.00B | $-0.00B | $-0.00B | $--0.00B | $-1.08K |
Net Change in Cash | $6.33M | $-843.76K | $-2.38M | $2.85M | $-124.41K | $-444.58K | $-109.06K | $- | $1.18M |
Cash at End of Period | $6.43M | $100.03K | $943.80K | $3.33M | $476.86K | $601.26K | $1.05M | $1.15M | $1.57M |
Cash at Beginning of Period | $100.03K | $943.80K | $3.33M | $476.86K | $601.26K | $1.05M | $1.15M | $1.15M | $389.98K |
Operating Cash Flow | $-381.68K | $-780.69K | $-2.32M | $-2.39M | $-514.40K | $-768.76K | $-885.51K | $-506.40K | $-590.14K |
Capital Expenditure | $-50.00K | $-62.32K | $-59.16K | $- | $- | $- | $-11.19K | $1.40K | $-29.99K |
Free Cash Flow | $-431.68K | $-843.01K | $-2.38M | $-2.39M | $-514.40K | $-768.76K | $-896.70K | $-505.00K | $-620.13K |
Elevai Labs, Common Stock Dividends
Explore Elevai Labs, Common Stock's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|
Related Metrics
Explore detailed financial metrics and analysis for ELAB.